Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge

Alexander Bukreyev, Andrea Marzi, Friederike Feldmann, Liqun Zhang, Lijuan Yang, Jerrold M. Ward, David W. Dorward, Raymond J. Pickles, Brian R. Murphy, Heinz Feldmann, Peter L. Collins

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We generated a new live-attenuated vaccine against Ebola virus (EBOV) based on a chimeric virus HPIV3/ΔF-HN/EboGP that contains the EBOV glycoprotein (GP) as the sole transmembrane envelope protein combined with the internal proteins of human parainfluenza virus type 3 (HPIV3). Electron microscopy analysis of the virus particles showed that they have an envelope and surface spikes resembling those of EBOV and a particle size and shape resembling those of HPIV3. When HPIV3/ΔF-HN/EboGP was inoculated via apical surface of an in vitro model of human ciliated airway epithelium, the virus was released from the apical surface; when applied to basolateral surface, the virus infected basolateral cells but did not spread through the tissue. Following intranasal (IN) inoculation of guinea pigs, scattered infected cells were detected in the lungs by immunohistochemistry, but infectious HPIV3/ΔF-HN/EboGP could not be recovered from the lungs, blood, or other tissues. Despite the attenuation, the virus was highly immunogenic, and a single IN dose completely protected the animals against a highly lethal intraperitoneal challenge of guinea pig-adapted EBOV.

Original languageEnglish (US)
Pages (from-to)348-361
Number of pages14
JournalVirology
Volume383
Issue number2
DOIs
StatePublished - Jan 20 2009
Externally publishedYes

Fingerprint

Human parainfluenza virus 3
Ebolavirus
Paramyxoviridae Infections
Glycoproteins
Membrane Proteins
Viruses
Virion
Ebola Vaccines
Guinea Pigs
Lung
Attenuated Vaccines
Particle Size
Electron Microscopy
Proteins
Epithelium
Immunohistochemistry

Keywords

  • Antibody
  • Ebola virus
  • Vaccine
  • Vector

ASJC Scopus subject areas

  • Virology

Cite this

Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. / Bukreyev, Alexander; Marzi, Andrea; Feldmann, Friederike; Zhang, Liqun; Yang, Lijuan; Ward, Jerrold M.; Dorward, David W.; Pickles, Raymond J.; Murphy, Brian R.; Feldmann, Heinz; Collins, Peter L.

In: Virology, Vol. 383, No. 2, 20.01.2009, p. 348-361.

Research output: Contribution to journalArticle

Bukreyev, A, Marzi, A, Feldmann, F, Zhang, L, Yang, L, Ward, JM, Dorward, DW, Pickles, RJ, Murphy, BR, Feldmann, H & Collins, PL 2009, 'Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge', Virology, vol. 383, no. 2, pp. 348-361. https://doi.org/10.1016/j.virol.2008.09.030
Bukreyev, Alexander ; Marzi, Andrea ; Feldmann, Friederike ; Zhang, Liqun ; Yang, Lijuan ; Ward, Jerrold M. ; Dorward, David W. ; Pickles, Raymond J. ; Murphy, Brian R. ; Feldmann, Heinz ; Collins, Peter L. / Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. In: Virology. 2009 ; Vol. 383, No. 2. pp. 348-361.
@article{14d29c09a08944998feeface43a00a79,
title = "Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge",
abstract = "We generated a new live-attenuated vaccine against Ebola virus (EBOV) based on a chimeric virus HPIV3/ΔF-HN/EboGP that contains the EBOV glycoprotein (GP) as the sole transmembrane envelope protein combined with the internal proteins of human parainfluenza virus type 3 (HPIV3). Electron microscopy analysis of the virus particles showed that they have an envelope and surface spikes resembling those of EBOV and a particle size and shape resembling those of HPIV3. When HPIV3/ΔF-HN/EboGP was inoculated via apical surface of an in vitro model of human ciliated airway epithelium, the virus was released from the apical surface; when applied to basolateral surface, the virus infected basolateral cells but did not spread through the tissue. Following intranasal (IN) inoculation of guinea pigs, scattered infected cells were detected in the lungs by immunohistochemistry, but infectious HPIV3/ΔF-HN/EboGP could not be recovered from the lungs, blood, or other tissues. Despite the attenuation, the virus was highly immunogenic, and a single IN dose completely protected the animals against a highly lethal intraperitoneal challenge of guinea pig-adapted EBOV.",
keywords = "Antibody, Ebola virus, Vaccine, Vector",
author = "Alexander Bukreyev and Andrea Marzi and Friederike Feldmann and Liqun Zhang and Lijuan Yang and Ward, {Jerrold M.} and Dorward, {David W.} and Pickles, {Raymond J.} and Murphy, {Brian R.} and Heinz Feldmann and Collins, {Peter L.}",
year = "2009",
month = "1",
day = "20",
doi = "10.1016/j.virol.2008.09.030",
language = "English (US)",
volume = "383",
pages = "348--361",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge

AU - Bukreyev, Alexander

AU - Marzi, Andrea

AU - Feldmann, Friederike

AU - Zhang, Liqun

AU - Yang, Lijuan

AU - Ward, Jerrold M.

AU - Dorward, David W.

AU - Pickles, Raymond J.

AU - Murphy, Brian R.

AU - Feldmann, Heinz

AU - Collins, Peter L.

PY - 2009/1/20

Y1 - 2009/1/20

N2 - We generated a new live-attenuated vaccine against Ebola virus (EBOV) based on a chimeric virus HPIV3/ΔF-HN/EboGP that contains the EBOV glycoprotein (GP) as the sole transmembrane envelope protein combined with the internal proteins of human parainfluenza virus type 3 (HPIV3). Electron microscopy analysis of the virus particles showed that they have an envelope and surface spikes resembling those of EBOV and a particle size and shape resembling those of HPIV3. When HPIV3/ΔF-HN/EboGP was inoculated via apical surface of an in vitro model of human ciliated airway epithelium, the virus was released from the apical surface; when applied to basolateral surface, the virus infected basolateral cells but did not spread through the tissue. Following intranasal (IN) inoculation of guinea pigs, scattered infected cells were detected in the lungs by immunohistochemistry, but infectious HPIV3/ΔF-HN/EboGP could not be recovered from the lungs, blood, or other tissues. Despite the attenuation, the virus was highly immunogenic, and a single IN dose completely protected the animals against a highly lethal intraperitoneal challenge of guinea pig-adapted EBOV.

AB - We generated a new live-attenuated vaccine against Ebola virus (EBOV) based on a chimeric virus HPIV3/ΔF-HN/EboGP that contains the EBOV glycoprotein (GP) as the sole transmembrane envelope protein combined with the internal proteins of human parainfluenza virus type 3 (HPIV3). Electron microscopy analysis of the virus particles showed that they have an envelope and surface spikes resembling those of EBOV and a particle size and shape resembling those of HPIV3. When HPIV3/ΔF-HN/EboGP was inoculated via apical surface of an in vitro model of human ciliated airway epithelium, the virus was released from the apical surface; when applied to basolateral surface, the virus infected basolateral cells but did not spread through the tissue. Following intranasal (IN) inoculation of guinea pigs, scattered infected cells were detected in the lungs by immunohistochemistry, but infectious HPIV3/ΔF-HN/EboGP could not be recovered from the lungs, blood, or other tissues. Despite the attenuation, the virus was highly immunogenic, and a single IN dose completely protected the animals against a highly lethal intraperitoneal challenge of guinea pig-adapted EBOV.

KW - Antibody

KW - Ebola virus

KW - Vaccine

KW - Vector

UR - http://www.scopus.com/inward/record.url?scp=58149129187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149129187&partnerID=8YFLogxK

U2 - 10.1016/j.virol.2008.09.030

DO - 10.1016/j.virol.2008.09.030

M3 - Article

C2 - 19010509

AN - SCOPUS:58149129187

VL - 383

SP - 348

EP - 361

JO - Virology

JF - Virology

SN - 0042-6822

IS - 2

ER -